CATEGORIES: CMT Summit | Research
rare patient advocacy symposium

Allison Moore Speaker at 2018 Rare Patient Advocacy Symposium

by | Jul 26, 2018 | 0 comments

allison mooreOn May 19, the Hereditary Neuropathy Foundation (HNF) participated in the Rare Patient Advocacy Symposium in partnership with Penn Medicine Orphan Disease Center and Global Genes. HNF’s CEO/Founder, Allison Moore, spoke on the importance of the “Patient’s Voice” and “Patients as Key Opinion Leaders and Partners In Research and Clinical Development”.

The presentation highlighted the vital role the patients play in the development of drugs and treatments for the CMT community. Moore presented the key steps and processes used to acquire our upcoming Externally-led Patient-Focused Drug Development (PFDD) meeting with FDA officials and other stakeholders, as well as the tools HNF will use to inform the FDA on what matters most to patients and how they view the benefits and risks of potential treatments.

Attendees were also briefed on the wide spectrum of Charcot- Marie-Tooth (CMT) symptoms and severities, as well as on the urgency for collecting patient data and the importance of natural history studies. HNF’s innovative proprietary patient registry — Global Registry for Inherited Neuropathies (GRIN), will help to improve drug discovery, clinical trials design and the acceleration of therapy development and regulatory approvals. HNF has been collecting patient data for close to 5 years, part of the organization’s continued commitment to making patients a key part of the research process and clinical development.

Moore has extensive experience in patient engagement methods, with an emphasis on identifying the gaps that have been hindering CMT patient care, standard of care guidelines, issues with patients having delayed and accurate diagnosis, and the need for improved clinical outcome measures and endpoints to support clinical trials.

The symposium was another valuable opportunity to network and partner with like-minded advocacy groups and key players to exchange valuable resources. HNF is dedicated to remaining on the cutting-edge of new pathways, technologies and collaborations like those displayed at the symposium. HNF is grateful to Global Genes for inviting us to participate!

We will continue to work tirelessly to provide the optimal treatment path for our CMT families, and look forward to meeting many of you at our “Voice of the Patient” Weekend, Sept 28-29.

Learn more on this topic

Related Blog Posts

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news